RxSight reports preliminary Q4 2022 revenue $16.1M, up 91% YoY; full-year $49.0M, up 117%

RxSight, Inc.

2022-FY EPS reported -$2.41 revenue$49,005,000

Q4 2022 revenue $16.1M (+91% YoY); 57 LDDs sold, installed base 400 LDDs as of Dec 31, 2022.
Full-year 2022 revenue $49.0M (+117% YoY); 25,284 LALs sold.
Preliminary cash, equivalents & short-term investments $105.8M, including $6.0M ATM net proceeds.
Management expects continued growth in 2023; audited results targeted for early March 2023.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

RxSight, Inc. reported fourth quarter and full-year 2022 results: revenue approximately $16.1 million.

Period: fourth quarter and full-year 2022
Revenue: approximately $16.1 million
Result: preliminary results

Exact text from the filing

operational results for the fourth quarter and full-year 2022. Preliminary Unaudited Results • Preliminary unaudited fourth quarter 2022 revenue is expected to be approximately $16.1 million, representing growth of approximately 91% compared to the prior year period, driven by: o The sale of 57 Light Delivery Devices (LDDTMs), expanding the installed base to 400 LDDs

View on SEC.gov

Browse all earnings releases →

RxSight, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-000394

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.